BioSpace News Archive

Apteryx Imaging Inc. (“Apteryx” or the “Company”) (TSXV:XRAY) is pleased to announce the closing of the previously announced acquisition of the Company by a PDDS Buyer, LLC (“Planet DDS”) subsidiary

Vision Impact Institute encourages legislators and parents to continue to prioritize good vision for children amid changes to education due to Covid-19.

- In lieu of an in-person update to the media, Dr. Theresa Tam , Canada’s Chief Public Health Officer, issued the following statement today: “There have been 120,421 cases of COVID-19 in Canada , including 8,991 deaths. 88% of people have now recovered. Labs across Canada have tested 4,541,747 people for COVID-19 to date. Over the p

Medicus IT, a leading, healthcare-focused managed services provider (MSP), announced today that Inc. magazine has named it one of the Top 5000 Fastest-Growing Private Companies in the country. This is Medicus IT’s sixth year earning a spot on the prestigious list. “It is a tremendous honor to receive this recognition for a

The 2020 Atlanta Inno Blazer Award in Health Care and Medicine recognizes BioIQ’s efforts to improve COVID-19 testing access and turnaround times as employers, universities, and government agencies seek to safely reopen [12-August-2020] ATLANTA , Aug. 12, 2020 /PRNewswire/ -- BioIQ , a healthcare engagement and clinical adherence technology platform company, was rece

Paper is the first to define the requirements for establishment of dedicated adult sickle cell disease treatment centers

On the heels of a series of successful virtual webinars, The Sickle Cell Foundation of Tennessee will launch the Sickle Cell Today podcast on the KUDZUKIAN Network. The first of the four episode series debuted on Monday, August 10 th and will air once a week going forward. Episodes will focus on pain management, quality of li

Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share.

Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020

Softgel capsules are drug formulations which are unique in their packaging of the drug concentrate in a manner that increases efficiency of drug delivery.